TC Biopharm (Holdings) Company Description

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, develops immunotherapy products based on its allogeneic gamma delta T cell platform in the United States.

Its product pipeline comprises OmnImmune (TCB002), an allogeneic unmodified gamma-delta T cell therapy product which is in phase 2/3 clinical trial for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections, as well as cancers.

The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

TC Biopharm (Holdings) Plc

Country	United Kingdom
Founded	2013
Industry	Biotechnology
Sector	Healthcare
Employees	39
CEO	Bryan Kobel

Contact Details

Address: Maxim 1 Motherwell, ML1 4WR United Kingdom
Phone	44 14 1433 7557
Website	tcbiopharm.com

Stock Details

Ticker Symbol	TCBPY
Exchange	OTCMKTS
Fiscal Year	January - December
Reporting Currency	GBP
SIC Code	2836

Key Executives

Name	Position
Bryan Leland Kobel	Chief Executive Officer and Director
Martin Edward Thorp	Chief Financial Officer and Director
Christopher Camarra	Executive Vice President of Communications
Dr. Lauren Bor Ph.D.	Head of Commercial Development Division